Abstract 447P
Background
The addition of chemotherapy to Gefitinib improved outcomes in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations in this trial, these results have already been published. Here we analysed the quality of life (QoL) data of patients in this study to determine the impact of the addition of chemotherapy to Gefitinib on QoL.
Methods
This was a phase III randomized trial in treatment-naive patients with advanced NSCLC with an EGFR-sensitizing mutation and ECOG PS of 0 -2 receiving first-line palliative therapy. Patients were randomized 1:1 to receive either gefitinib 250 mg PO once a day (Gef) or gefitinib 250 mg PO once a day with Pemetrexed (500 mg/m2) + Carboplatin (AUC5) IV every 3 weeks for 4 cycles, followed by maintenance pemetrexed (gefitinib plus chemotherapy [Gef+C]). The primary endpoint was PFS; QoL was a key secondary endpoint. QoL was assessed using the EORTC QLQ C-30 and LC 13 questionnaires and their validated translations. QoL was collected at 2 monthly intervals [60 (+/-15) days]. The mean QoL scores for both arms were plotted and compared between the two arms at each time point using the Mann-Whitney Test. Sensitivity analysis was performed. The mixed linear model analysis is used to study the impact of treatment arms and time on QoL scores while considering participant variability.
Results
In the linear mixed model analysis (LMA), there was no significant impact on the global health status (QL) scores between the 2 arms (p= 0.5007). However, there was a significant change in the global health status scores in both arms over time (p= 0.0420). In the LMA there were no significant differences in the other function scales between the 2 arms. The scores for the symptoms scale had significantly improved for pain (p = 0.0351), dyspnoea (p = 0.0483), diarrhea (p = 0.0243), sore mouth (p = 0.0283), pain in the arm or shoulder (p = 0.0315), pain in other parts (p = 0.0273) improved over time in the Gef+C arm as compared Gef arm.
Conclusions
The addition of chemotherapy to Gefitinib improved survival outcomes (PFS an dOS) without a significant adverse impact on quality of life.
Clinical trial identification
CTRI/2016/08/007149.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tata Memorial Center Research Administration Council and unrestricted educational grants from Dr. Reddy’s Laboratories, Fresenius Kabi India, Alkem Laboratories, Natco Pharma, BDR Pharmaceuticals, and Lung Cancer Consortium India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract